Clean intermittent catheterization in Parkinson’s disease: a case report
Objective: Describe the interdisciplinary actions that resulted in the therapeutic indication of a clean intermittent bladder catheterization in a patient with detrusor areflexia related to…Cerebrospinal Fluid Levels of Coenzyme Q10 are Reduced in Multiple System Atrophy
Objective: To assess CSF levels of coenzyme Q10 in multiple system atrophy (MSA) vs. Parkinson’s disease (PD), progressive supranuclear palsy (PSP), and control subjects without…Freezing of gait is an early clinical feature of progressive supranuclear palsy
Objective: We attempted to identify any sign or symptom to diagnose progressive supranuclear palsy (PSP) earlier. Background: Early clinical diagnosis of progressive supranuclear palsy PSP…Dysphagia in PSP
Objective: To characterize the nature of dysphagia accompanying progressive supranuclear palsy (PSP). Background: Dysphagia is a frequent symptom of PSP, typically occurring early in the…Neuropsychiatric and Cognitive Predictors of Early Diagnosis of Progressive Supranuclear Palsy
Objective: To define differences of neuropsychiatric and neuropsychological profile among Progressive Supranuclear Palsy (PSP) -Richardson syndrome (PSP-RS), PSP-parkinsonism (PSP-P), and Parkinson’s disease (PD), in order…Effect of low frequency stimulation on freezing of gait in a PSP patient with bilateral STN DBS
Objective: To study the effect of low frequency stimulation (LFS) on freezing of gait (FOG) in a progressive supranuclear palsy (PSP) patient with bilateral STN…Understanding the illness experience of people living with Parkinson’s disease: A mixed methods study
Objective: This study aimed to (i) examine the relationship of psychological distress and HRQoL and (ii) explore the illness experience among people with PD. Background:…The FDA is listening: Integrating the voice of the patient in drug development for Parkinson’s and Huntington’s diseases.
Objective: To present highlights from the Patient-Focused Drug Development (PFDD) meetings held at FDA for Parkinson’s disease (PD) and Huntington’s disease (HD) to raise awareness…Factors that contribute to the greatest levels of caregiver strain in Parkinson’s
Objective: To identify factors that cause the greatest levels of caregiver strain in moderate to advanced Parkinson’s Disease (PD) Background: Many people with PD (PwP)…Treatment Outcomes for Deep Brain Stimulation in Sex-Linked Dystonia Parkinsonism (XDP, DYT3) Up To 60 Months Follow-up – A Case Series
Objective: This case series presented the treatment outcomes of the eight (8) XDP patients who underwent DBS in a tertiary hospital and compared it to previous…
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 155
- Next Page »